XML 29 R21.htm IDEA: XBRL DOCUMENT
v3.24.2

Segment Reporting (Tables) | 6 Months Ended
--- | ---
May 31, 2024
Segment Reporting [Abstract] |
Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, and Interest Expense and Assets by Segment | The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, and interest expense for the three and six months ended May 31, 2024 and 2023:
|  | For the three months ended May 31, |
|  | 2024 |  |  | 2023 |
Net revenue: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 7,965,500 |  |  | $ | 7,581,697 |
PrepaCyte CB |  |  | 35,834 |  |  |  | 27,177 |
Public cord blood banking |  |  | 41,477 |  |  |  | 163,816 |
Total net revenue |  | $ | 8,042,811 |  |  | $ | 7,772,690 |
Cost of sales: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 1,830,453 |  |  | $ | 1,802,882 |
PrepaCyte CB |  |  | 10,380 |  |  |  | 9,328 |
Public cord blood banking |  |  | 183,917 |  |  |  | 330,976 |
Total cost of sales |  | $ | 2,024,750 |  |  | $ | 2,143,186 |
Operating profit: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 1,515,506 |  |  | $ | 1,184,513 |
PrepaCyte CB |  |  | 18,510 |  |  |  | 10,905 |
Public cord blood banking |  |  | (142,498 | ) |  |  | (167,520 | )
Total operating profit |  | $ | 1,391,518 |  |  | $ | 1,027,898 |
Depreciation and amortization: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 52,796 |  |  | $ | 273,776 |
PrepaCyte CB |  |  | 6,944 |  |  |  | 6,944 |
Public cord blood banking |  |  | 58 |  |  |  | 360 |
Total depreciation and amortization |  | $ | 59,798 |  |  | $ | 281,080 |
Interest expense: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 329,273 |  |  | $ | 469,952 |
PrepaCyte CB |  |  | — |  |  |  | — |
Public cord blood banking |  |  | — |  |  |  | — |
Total interest expense |  | $ | 329,273 |  |  | $ | 469,952 |
|  | For the six months ended May 31, |
|  | 2024 |  |  | 2023 |
Net revenue: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 15,771,022 |  |  | $ | 15,143,215 |
PrepaCyte CB |  |  | 38,834 |  |  |  | 59,377 |
Public cord blood banking |  |  | 85,190 |  |  |  | 394,513 |
Total net revenue |  | $ | 15,895,046 |  |  | $ | 15,597,105 |
Cost of sales: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 3,715,019 |  |  | $ | 3,490,132 |
PrepaCyte CB |  |  | 35,863 |  |  |  | 26,450 |
Public cord blood banking |  |  | 434,336 |  |  |  | 693,968 |
Total cost of sales |  | $ | 4,185,218 |  |  | $ | 4,210,550 |
Operating profit: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 2,573,225 |  |  | $ | 2,992,206 |
PrepaCyte CB |  |  | (10,918 | ) |  |  | 19,038 |
Public cord blood banking |  |  | (349,566 | ) |  |  | (300,175 | )
Total operating profit |  | $ | 2,212,741 |  |  | $ | 2,711,069 |
Depreciation and amortization: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 78,675 |  |  | $ | 547,315 |
PrepaCyte CB |  |  | 13,889 |  |  |  | 13,889 |
Public cord blood banking |  |  | 420 |  |  |  | 720 |
Total depreciation and amortization |  | $ | 92,984 |  |  | $ | 561,924 |
Interest expense: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 585,732 |  |  | $ | 936,183 |
PrepaCyte CB |  |  | — |  |  |  | — |
Public cord blood banking |  |  | — |  |  |  | — |
Total interest expense |  | $ | 585,732 |  |  | $ | 936,183 |
The following table shows the assets by segment as of May 31, 2024 and November 30, 2023:
|  | As of |  |  | As of |
|  | May 31, 2024 |  |  | November 30, 2023 |
Assets: |  |  |  |  |  |
Umbilical cord blood and cord tissue stem cell service |  | $ | 56,915,873 |  |  | $ | 55,471,149 |
PrepaCyte CB |  |  | 111,921 |  |  |  | 148,040 |
Public cord blood banking |  |  | 5,538,802 |  |  |  | 5,601,581 |
Total assets |  | $ | 62,566,596 |  |  | $ | 61,220,770 |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration